

Emma C Thomson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7890399/publications.pdf>

Version: 2024-02-01

90
papers

7,076
citations

182225

30
h-index

81351

76
g-index

112
all docs

112
docs citations

112
times ranked

16707
citing authors

#	ARTICLE	IF	CITATIONS
1	A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi, suggests a historic mechanism of transmission. <i>Journal of Viral Hepatitis</i> , 2022, , .	1.0	2
2	Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. <i>Nature Immunology</i> , 2022, 23, 40-49.	7.0	145
3	Women in the European Virus Bioinformatics Center. <i>Viruses</i> , 2022, 14, 1522.	1.5	1
4	Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. <i>Cell</i> , 2021, 184, 64-75.e11.	13.5	843
5	Genomic epidemiology reveals multiple introductions of SARS-CoV-2 from mainland Europe into Scotland. <i>Nature Microbiology</i> , 2021, 6, 112-122.	5.9	88
6	Analysis of an Ebola virus disease survivor whose host and viral markers were predictive of death indicates the effectiveness of medical countermeasures and supportive care. <i>Genome Medicine</i> , 2021, 13, 5.	3.6	9
7	A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. <i>PLoS Biology</i> , 2021, 19, e3001091.	2.6	163
8	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. <i>Cell</i> , 2021, 184, 1171-1187.e20.	13.5	541
9	Subgenomic RNA identification in SARS-CoV-2 genomic sequencing data. <i>Genome Research</i> , 2021, 31, 645-658.	2.4	48
10	SARS-CoV-2 within-host diversity and transmission. <i>Science</i> , 2021, 372, .	6.0	278
11	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. <i>Nature</i> , 2021, 596, 417-422.	13.7	549
12	Mosquito-borne arboviruses in Uganda: history, transmission and burden. <i>Journal of General Virology</i> , 2021, 102, .	1.3	2
13	Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1256-1264.	1.0	16
14	Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units – A high risk community-hospital interface. <i>Journal of Infection</i> , 2021, 83, 96-103.	1.7	12
15	Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens. <i>Journal of Hepatology</i> , 2021, 75, 462-473.	1.8	27
16	In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. <i>PLoS Pathogens</i> , 2021, 17, e1009929.	2.1	108
17	Paper microfluidic implementation of loop mediated isothermal amplification for early diagnosis of hepatitis C virus. <i>Nature Communications</i> , 2021, 12, 6994.	5.8	43
18	Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. <i>PLoS Pathogens</i> , 2021, 17, e1010022.	2.1	139

#	ARTICLE	IF	CITATIONS
19	Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2020, 23, 180-190.	0.1	1
20	Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report. <i>Clinical Infectious Diseases</i> , 2020, 71, 2872-2879.	2.9	17
21	Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 935.	0.7	7
22	Distemper, extinction, and vaccination of the Amur tiger. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 31954-31962.	3.3	33
23	STROBE-metagenomics: a STROBE extension statement to guide the reporting of metagenomics studies. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e251-e260.	4.6	40
24	Transmission of hepatitis C virus in HIV-positive and PrEP-using MSM in England. <i>Journal of Viral Hepatitis</i> , 2020, 27, 721-730.	1.0	16
25	COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. <i>Cardiovascular Research</i> , 2020, 116, 1666-1687.	1.8	1,074
26	Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020. <i>Eurosurveillance</i> , 2020, 25, .	3.9	186
27	Metagenomic next-generation sequencing aids the diagnosis of viral infections in febrile returning travellers. <i>Journal of Infection</i> , 2019, 79, 383-388.	1.7	45
28	Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C. <i>Journal of Hepatology</i> , 2019, 71, 1099-1105.	1.8	52
29	Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. <i>Journal of Infection</i> , 2019, 79, 503-512.	1.7	23
30	PS-181-Unacceptably low SVR rates in African patients with unusual HCV sub-genotypes : Implications for global elimination. <i>Journal of Hepatology</i> , 2019, 70, e111-e112.	1.8	3
31	LBP-34-Effect of Resistance Associated Substitutions on Retreatment of HCV infected patients with prior failure to Direct Acting Antiviral Therapy. <i>Journal of Hepatology</i> , 2019, 70, e158-e159.	1.8	0
32	THU-121-Real world outcomes from NS5a treatment failures undergoing therapy with sofosbuvir/velpatasvir/voxilaprevir and sofosbuvir/ glecaprevir/pibrentasvir. <i>Journal of Hepatology</i> , 2019, 70, e212.	1.8	1
33	A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2019, 22, 693-703.	0.1	13
34	Convalescent plasma therapy for persistent hepatitis E virus infection. <i>Journal of Hepatology</i> , 2019, 71, 434-438.	1.8	17
35	Development of a World Health Organization International Reference Panel for different genotypes of hepatitis E virus for nucleic acid amplification testing. <i>Journal of Clinical Virology</i> , 2019, 119, 60-67.	1.6	14
36	Interpreting Viral Deep Sequencing Data with GLUE. <i>Viruses</i> , 2019, 11, 323.	1.5	29

#	ARTICLE	IF	CITATIONS
37	Highly Diverse Hepatitis C Strains Detected in Sub-Saharan Africa Have Unknown Susceptibility to Direct-Acting Antiviral Treatments. <i>Hepatology</i> , 2019, 69, 1426-1441.	3.6	36
38	Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. <i>ELife</i> , 2019, 8, .	2.8	28
39	Reply to: "Reply to: "Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries" Journal of Hepatology, 2018, 68, 864-866.	1.8	2
40	GLUE: a flexible software system for virus sequence data. <i>BMC Bioinformatics</i> , 2018, 19, 532.	1.2	84
41	Homeless medical respite service provision in the UK. <i>Housing, Care and Support</i> , 2018, 22, 40-53.	0.2	5
42	Quasispecies Changes with Distinctive Point Mutations in the Hepatitis C Virus Internal Ribosome Entry Site (IRES) Derived from PBMCs and Plasma. <i>Advances in Virology</i> , 2018, 2018, 1-9.	0.5	5
43	Grazoprevir/elbasvir dosing according to viral load and NS5A resistance: real world confirmation of the efficacy of EASL guidance. <i>Journal of Hepatology</i> , 2018, 68, S287-S288.	1.8	0
44	Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. <i>Nature Genetics</i> , 2017, 49, 666-673.	9.4	129
45	Hepatitis C and the absence of genomic data in low-income countries: a barrier on the road to elimination?. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 700-701.	3.7	18
46	Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries. <i>Journal of Hepatology</i> , 2017, 67, 1348-1350.	1.8	31
47	Tracking TCR β Sequence Clonotype Expansions during Antiviral Therapy Using High-Throughput Sequencing of the Hypervariable Region. <i>Frontiers in Immunology</i> , 2016, 7, 131.	2.2	4
48	Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2470-2484.	1.8	112
49	Late Ebola virus relapse causing meningoencephalitis: a case report. <i>Lancet, The</i> , 2016, 388, 498-503.	6.3	291
50	Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? <i>Epidemiological and Modeling Insights. Clinical Infectious Diseases</i> , 2016, 62, 1072-1080.	2.9	122
51	Comparison of next Generation Sequencing Technologies for the Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes. <i>Journal of Hepatology</i> , 2016, 64, S415.	1.8	1
52	Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-infected patients with mild liver disease. <i>Journal of Viral Hepatitis</i> , 2016, 23, 123-129.	1.0	3
53	Efficacy of Sofosbuvir/Ledipasvir in Treating Genotype 1 and 4 Hepatitis C for 8/12 Weeks: Results from a Difficult to Treat Cohort. <i>Journal of Hepatology</i> , 2016, 64, S805.	1.8	1
54	Can Targeted HCV Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Amongst Men who Have Sex with Men in the UK - Epidemiological and Modelling Insights. <i>Journal of Hepatology</i> , 2016, 64, S207-S208.	1.8	0

#	ARTICLE	IF	CITATIONS
55	MAIT cells are activated during human viral infections. <i>Nature Communications</i> , 2016, 7, 11653.	5.8	428
56	Two cases of possible transmitted drug-resistant HIV: likely HIV superinfection and unmasking of pre-existing resistance. <i>International Journal of STD and AIDS</i> , 2016, 27, 66-69.	0.5	9
57	Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection. <i>Journal of Virology</i> , 2016, 90, 4530-4543.	1.5	28
58	Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140241.	1.8	33
59	Waiting time and transplantation for hepatocellular cancer: A balance between tempus fugit and carpe diem. <i>Hepatology</i> , 2015, 61, 1438-1439.	3.6	2
60	Reply. <i>Hepatology</i> , 2015, 61, 1438-1438.	3.6	0
61	Genetic characterization of human coxsackievirus A6 variants associated with atypical hand, foot and mouth disease: a potential role of recombination in emergence and pathogenicity. <i>Journal of General Virology</i> , 2015, 96, 1067-1079.	1.3	55
62	Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. <i>Journal of Clinical Virology</i> , 2015, 65, 50-53.	1.6	24
63	Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment. <i>Hepatology</i> , 2015, 61, 88-97.	3.6	36
64	P0734 : Healthcare utilisation following treatment of HIV/HCV patients with mild liver disease. <i>Journal of Hepatology</i> , 2015, 62, S600.	1.8	0
65	P1289 : Understanding and preventing the HCV epidemic among men who have sex with men in the UK: A mathematical modelling analysis. <i>Journal of Hepatology</i> , 2015, 62, S843.	1.8	1
66	P230 OPTIMISATION OF A NEXT-GENERATION SEQUENCING PIPELINE FOR THE ANALYSIS OF THE HEPATITIS C VIRUS GENOME FROM HISTORICAL FORMALIN-FIXED PARAFFIN-EMBEDDED LIVER BIOPSIES. <i>Journal of Hepatology</i> , 2014, 60, S142.	1.8	0
67	Unusual oral mucosa damage during telaprevir treatment of chronic hepatitis C. <i>Hepatology</i> , 2014, 59, 1209-1210.	3.6	2
68	Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. <i>Aids</i> , 2013, 27, 2485-2488.	1.0	21
69	Short-Course Antiretroviral Therapy in Primary HIV Infection. <i>New England Journal of Medicine</i> , 2013, 368, 207-217.	13.9	194
70	PTU-119...Histopathology and Long Term Clinical Prognosis in HCV. does the Biopsy still have anything to Add?. <i>Gut</i> , 2013, 62, A94.2-A95.	6.1	0
71	1283 ELEVATED ALT IS UBIQUITOUS IN PATIENTS WITH HIV AND FATTY LIVER IS BOTH COMMON AND UNDERDIAGNOSED. <i>Journal of Hepatology</i> , 2012, 56, S506-S507.	1.8	0
72	1344 NON-CIRRHOTIC PORTAL HYPERTENSION IN HIV INFECTION HAS A VARIED CLINICAL PHENOTYPE AND IS ASSOCIATED WITH DIDANOSINE AND THROMBOPHILIA: REVIEW OF TWENTY-ONE CASES. <i>Journal of Hepatology</i> , 2012, 56, S528-S529.	1.8	0

#	ARTICLE	IF	CITATIONS
73	Acute HCV/HIV Coinfection Is Associated with Cognitive Dysfunction and Cerebral Metabolite Disturbance, but Not Increased Microglial Cell Activation. PLoS ONE, 2012, 7, e38980.	1.1	30
74	The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals. Journal of General Virology, 2011, 92, 2227-2236.	1.3	21
75	Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut, 2011, 60, 837-845.	6.1	146
76	Dynamic Coinfection with Multiple Viral Subtypes in Acute Hepatitis C. Journal of Infectious Diseases, 2010, 202, 1770-1779.	1.9	31
77	B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nature Communications, 2010, 1, 102.	5.8	62
78	Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. Aids, 2009, 23, 89-93.	1.0	155
79	Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals?. Journal of Viral Hepatitis, 2009, 17, 419-426.	1.0	24
80	Diagnosing acute hepatitis C in HIV-infected patients: Nucleic acid testing compared with antibody and antigenâ€”antibody detecting methods. Journal of Clinical Virology, 2009, 44, 78-80.	1.6	12
81	400 DOES ACUTE HEPATITIS C INFECTION AFFECT THE CENTRAL NERVOUS SYSTEM IN HIV INFECTED INDIVIDUALS?. Journal of Hepatology, 2009, 50, S151.	1.8	0
82	Epidemiology of hepatitis C virus infection in HIVâ€”infected individuals. Journal of Viral Hepatitis, 2008, 15, 773-781.	1.0	5
83	671 REACTIVATION OF HEPATITIS C IN A PATIENT WITH ADVANCED HUMAN IMMUNODEFICIENCY VIRUS INFECTION. Journal of Hepatology, 2008, 48, S250.	1.8	1
84	Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom. Aids, 2008, 22, 666-668.	1.0	29
85	Response to â€œPersistence of Neuropsychologic Deficits Despite Long-Term Highly Active Antiretroviral Therapy in Patients With HIV-Related Neurocognitive Impairmentâ€” Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 656-657.	0.9	1
86	Response to Mallet et al., â€”Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patientsâ€”™. Aids, 2007, 21, 1494-1495.	1.0	25
87	Progressive multifocal leukoencephalopathy: prolonged survival in patients treated with protease inhibitors and cidofovir: a case series. Aids, 2006, 20, 791-793.	1.0	7
88	An elderly lady with sudden blindness and a sore foot. Journal of Infection, 2006, 52, e53-e54.	1.7	3
89	Advances in hepatitis B and C. Current Opinion in Infectious Diseases, 2004, 17, 449-459.	1.3	9
90	Septic thrombophlebitis with multiple pulmonary abscesses. Lancet Infectious Diseases, The, 2003, 3, 86.	4.6	2